Filing Analysis
Myriad Genetics is filing an amendment (8-K/A) to correct a clerical error in its previous earnings release regarding cash balances. The correction adjusts the beginning cash balance for the third quarter of 2025 downward from $101.0 million to $83.7 million.
🚩 Red Flags
- Correction of cash balance figures in an earnings release (though noted as clerical).
📋 Key Facts
- Filing is an Amendment No. 1 (Form 8-K/A) to a previously filed report dated November 3, 2025.
- The error specifically concerns the 'Cash, cash equivalents, and restricted cash at beginning of the period' on the Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2025.
- Corrected amount: $83.7 million.
- Original reported amount: $101.0 million.
- The company states this is a clerical error and no other changes were made to the financial results or press release.
Myriad Genetics, Inc. announced its quarterly financial results for the three-month period ending September 30, 2025.
📋 Key Facts
- Report date: November 3, 2025
- Reporting period: Three months ended September 30, 2025
- The filing includes an earnings release as Exhibit 99.1
- Signed by Benjamin R. Wheeler, Chief Financial Officer
Myriad Genetics, Inc. has entered into a Separation Agreement with former CFO Scott J. Leffler following his departure on September 2, 2025. The agreement includes a significant severance package and accelerated equity vesting.
🚩 Red Flags
- Significant cash outflow ($1.24M) for executive severance.
- Acceleration of time-based equity awards increases potential dilution/diluted share count impact.
📋 Key Facts
- Scott J. Leffler departed as CFO effective August 15, 2025; separation occurred Sept 2, 2025.
- Separation Agreement becomes effective October 9, 2025.
- Lump sum severance payment of $1,239,384 is required in exchange for restrictive covenants (non-compete, non-solicitation, non-disparagement).
- Time-based equity awards scheduled to vest within two years of the Separation Date will be accelerated and paid out monthly.
- Performance-based equity awards remain subject to original performance conditions through the end of the two-year period.
Myriad Genetics announced the resignation of Natalie Munk as Chief Accounting Officer, effective October 24, 2025. The company's CFO, Benjamin R. Wheeler, will assume the role of Principal Accounting Officer upon her departure.
🚩 Red Flags
- Departure of a key financial officer (CAO) can create temporary administrative gaps in financial reporting oversight.
📋 Key Facts
- Natalie Munk resigned from her position as SVP, Chief Accounting Officer and principal accounting officer on September 29, 2025.
- Munk's resignation is effective October 24, 2025.
- The company stated the departure is not due to any disagreement regarding operations, policies, or practices.
- Benjamin R. Wheeler (CFO) will take over as Principal Accounting Officer on October 24, 2025.
- Wheeler has been with the company for 13 years and previously served as SVP of Finance and Treasury and Corporate Controller.
Myriad Genetics announced the departure of CFO Scott J. Leffler, effective August 15, 2025. Ben R. Wheeler, a long-time company veteran and former SVP of Finance and Treasury, has been appointed as the new CFO.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (effective immediately/short notice).
📋 Key Facts
- Scott J. Leffler departed as CFO on August 15, 2025; he will remain as a non-executive employee for an interim period to assist with transition.
- Ben R. Wheeler appointed CFO effective August 16, 2025.
- Mr. Wheeler has been with the company since December 2011 in various finance and controller roles.
- Wheeler's new compensation includes a $490,000 annual base salary and an annual target cash bonus of 75% of his base salary.
- The appointment included an initial grant of 60,000 time-based RSUs and 60,000 performance-based RSUs.
Myriad Genetics, Inc. filed an 8-K to announce its quarterly financial results for the three months ended June 30, 2025. The filing serves as a formal announcement of the earnings release dated August 5, 2025.
📋 Key Facts
- Reporting period: Three months ended June 30, 2025.
- Earnings release date: August 5, 2025.
- The filing includes Exhibit 99.1 containing the earnings release.
Myriad Genetics entered into a $200 million credit facility on July 31, 2025, consisting of a $125 million initial term loan and up to $75 million in delayed draw loans. The funds are intended for working capital and refinancing existing debt.
🚩 Red Flags
- High interest rate margin (6.50% over SOFR).
- Strict revenue-based financial covenants that increase quarterly.
- Secured by substantially all company assets.
- Repayment premium and exit fees apply to prepayments.
📋 Key Facts
- Total Credit Facility: $200 million ($125M initial term loan + $75M delayed draw).
- Closing Date: July 31, 2025.
- Maturity Date: July 31, 2030.
- Interest Rate: Greater of one-month SOFR plus 6.50% (plus a 2.50% floor).
- Security: Secured by substantially all assets of the Company and its material subsidiaries via a Pledge and Security Agreement.
- Repayment: Scheduled principal payments of 2.50% of unpaid principal starting September 30, 2029.
- Financial Covenant: Minimum trailing twelve-month revenue test starting at $615M (Dec 2025) and scaling to $974M (Dec 2029).
Myriad Genetics, Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved several key items including the election of directors and an amendment to increase the share pool for equity incentives. The meeting also resulted in the ratification of Ernst & Young LLP as the company's independent auditor.
🚩 Red Flags
- Increased equity dilution via an additional 6.5 million shares added to the incentive plan pool.
📋 Key Facts
- Annual Meeting held on June 5, 2025; quorum reached at 89.21% (82,230,185 shares).
- Stockholders approved an amendment to the 2017 Equity Incentive Plan to increase the aggregate share pool by 6.5 million shares.
- Board approved increasing the annual cap on shares issued under the plan from 500,000 to 574,040 shares.
- Samraat S. Raha, Heiner Dreismann, PH.D., and Colleen F. Reitan were elected to the Board for terms expiring in 2028.
- Ernst & Young LLP was ratified as independent registered public accounting firm for FY ending Dec 31, 2025.
Myriad Genetics, Inc. announced its quarterly financial results for the three months ended March 31, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025
- Report date: May 6, 2025
- Filing includes an earnings release as Exhibit 99.1
- Signed by Scott J. Leffler, Chief Financial Officer
Myriad Genetics announced a major leadership transition involving the resignation of CEO Paul J. Diaz and the appointment of current COO Samraat S. Raha as his successor, effective April 30, 2025. The filing also includes significant new compensation agreements and severance packages for both the incoming CEO and the newly promoted COO.
🚩 Red Flags
- Significant leadership turnover at the top executive level (CEO and COO).
- Extensive severance/change of control provisions for incoming executives.
- The CEO's departure to a private equity firm could signal a shift in company focus or strategic direction.
📋 Key Facts
- CEO Paul J. Diaz to step down on April 30, 2025, to join Cressey & Company; will remain as a consultant for one year.
- Samraat S. Raha (current COO) appointed President and CEO effective April 30, 2025.
- Mark S. Verratti (current Chief Commercial Officer) appointed COO effective April 30, 2025.
- New CEO compensation includes $920,000 base salary and a one-time grant of 141,050 RSUs subject to performance targets.
- CEO severance package includes 200% of base salary plus target bonus in the event of termination without cause or separation for good reason.
- New COO compensation includes $660,000 base salary and a $400,000 retention bonus payable after July 1, 2027.
Myriad Genetics, Inc. issued a press release announcing preliminary financial results for the fourth quarter and full year ended December 31, 2024, while also providing financial guidance for the full year 2025.
🚩 Red Flags
- Forward-looking statements include risks regarding the ability to operate on a profitable basis.
- Risk noted regarding UnitedHealthcare's coverage decisions effective Q1 2025.
- Potential risk related to the transition of laboratory testing facilities.
📋 Key Facts
- Announced preliminary revenue, loss per share, and adjusted EPS for Q4 and FY 2024 on January 15, 2025.
- Introduced full year 2025 financial guidance.
- Actual financial results for the fourth quarter and full year 2024 are expected to be released in February 2025.
Myriad Genetics, Inc. announced the expansion of its Board of Directors from eight to nine members with the appointment of Mark S. Davis. Mr. Davis will serve as a Class I Director and an audit committee financial expert.
📋 Key Facts
- Board size increased from 8 to 9 members effective December 10, 2024.
- Mark S. Davis appointed as a Class I Director with a term expiring at the 2027 Annual Meeting.
- Mr. Davis is designated as an 'audit committee financial expert' per Regulation S-K.
- Appointment includes a restricted stock unit (RSU) award valued at $350,000, vesting in one year.
- Mr. Davis will serve on the Audit and Finance Committee.
The Company announced that a Delaware Court has approved a global settlement regarding two shareholder derivative lawsuits involving the company and its directors/officers. The settlement includes corporate governance reforms and an award of $950,000 in legal fees to be paid by the Company.
🚩 Red Flags
- Settlement involves allegations of breach of fiduciary duties by directors and officers.
- Direct cash outflow of $950,000 for legal fees/settlement costs.
📋 Key Facts
- The court approved the settlement on November 26, 2024.
- The settlement resolves two consolidated derivative actions: In re Myriad Genetics, Inc. Stockholder Derivative Litigation and Marcey v. Capone, et al.
- The Company will pay up to $950,000 in attorneys' fees and expenses.
- The settlement includes implementation of certain corporate governance reforms.
- The court dismissed the consolidated Derivative Action with prejudice.
Myriad Genetics announced its financial results for the third quarter ended September 30, 2024. The filing highlights significant risk regarding UnitedHealthcare's decision to cease coverage for certain GeneSight pharmacogenetic tests effective January 1, 2025.
🚩 Red Flags
- Significant revenue risk: Major payer (UnitedHealthcare) removing coverage for flagship product (GeneSight) in early 2025.
- Potential decline in sales and profit margins of existing tests due to reimbursement changes.
- Risk of inability to operate on a profitable basis if new products do not offset losses from coverage reductions.
📋 Key Facts
- Reported financial results for the three months ended September 30, 2024.
- UnitedHealthcare will no longer provide coverage for certain multi-gene panel pharmacogenetic tests (e.g., GeneSight) under commercial and individual exchange plans effective January 1, 2025.
- The company is actively engaging with UnitedHealthcare to seek a positive resolution regarding patient access to GeneSight.
Myriad Genetics disclosed preliminary third-quarter 2024 revenue guidance of $210M–$212M and reaffirmed its full-year 2024 revenue guidance of $835M–$845M. The announcement occurred in conjunction with an Investor Event held on October 9, 2024.
🚩 Red Flags
- Revenue guidance provided despite the loss of the EndoPredict business segment (divested Aug 1, 2024).
📋 Key Facts
- Preliminary Q3 2024 revenue expected: $210 million to $212 million.
- Reaffirmed full-year 2024 revenue guidance: $835 million to $845 million (previously issued Aug 6, 2024).
- Divestiture of EndoPredict business in Europe closed on August 1, 2024.
- Financial data is based on preliminary, unaudited internal reports.
Myriad Genetics has announced the discontinuation of a planned clinical economic utility study for its GeneSight testing product. The company determined that the non-GeneSight control group identified by their third-party vendor was not viable due to significant disparities in baseline hospital resource utilization and costs.
🚩 Red Flags
- Failure to produce conclusive clinical/economic utility data may impact reimbursement negotiations or insurance coverage expansion.
- Inability to establish a valid control group in retrospective studies can be a setback for companies seeking to prove value-based care outcomes.
📋 Key Facts
- The study aimed to compare hospital resource utilization and costs between GeneSight patients and a matched non-GeneSight control group.
- Initial results from part one of the study (reported April 2024) suggested a 29% decrease in general hospitalizations and a 39% decrease in psychiatric-related hospitalizations for GeneSight patients within 180 days.
- The company identified significant disparities between the test group and the control group, rendering any comparison unreliable.
- The analysis for part two of the study has been discontinued.
Myriad Genetics, Inc. announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal announcement of earnings and includes updated fiscal year 2024 guidance.
🚩 Red Flags
- Forward-looking statements include risks regarding the ability to operate on a profitable basis.
- Risks noted regarding potential inability to secure additional financing if needed.
- Risks mentioned regarding compliance with financial operating covenants under credit/lending agreements.
📋 Key Facts
- Reporting period: Three months ended June 30, 2024.
- Announcement date: August 6, 2024.
- The company provided updated fiscal year 2024 financial guidance in the attached earnings release (Exhibit 99.1).
- Management highlighted expectations for market share gains in prenatal testing and progress in 'Labs of the Future' initiatives.
Myriad Genetics, Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the election of two directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Quorum reached with 84,424,257 shares (approx. 93% of outstanding common stock) present via webcast or proxy.
- S. Louise Phanstiel and Daniel M. Skovronsky were elected to the Board of Directors for terms expiring at the 2027 Annual Meeting.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Advisory vote on executive compensation (Say-on-Pay) was approved.
Myriad Genetics has reached a global settlement regarding two shareholder derivative actions alleging breaches of fiduciary duty by current and former directors and officers. The settlement involves corporate governance reforms and the payment of up to $950,000 in legal fees.
🚩 Red Flags
- Shareholder derivative litigation alleging breach of fiduciary duties by directors and officers.
📋 Key Facts
- Settlement covers consolidated Delaware Court of Chancery case (Case No. 2021-0686-SG) and Federal District Court case (No. 1:21-cv-01320-MN).
- The settlement is subject to court approval, with a hearing scheduled for August 6, 2024.
- Terms include the implementation of certain corporate governance reforms.
- Plaintiffs' counsel seeks attorneys' fees and expenses not to exceed $950,000, to be paid by the Company.
Myriad Genetics, Inc. announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of earnings and includes forward-looking statements regarding product launches and clinical validation studies.
🚩 Red Flags
- Forward-looking statements include risks regarding the ability to operate on a profitable basis.
- Risks noted regarding potential inability to secure additional financing if needed.
- Potential risks related to insurance reimbursement levels for genetic tests.
📋 Key Facts
- Reported financial results for the three months ended March 31, 2024.
- Company is focusing on advancing new products and enhancing EMR (Electronic Medical Record) integrations.
- Management expressed intent to continue investing in precision medicine innovation.
Myriad Genetics, Inc. announced its financial results for the three months ended December 31, 2023. The filing includes forward-looking statements regarding upcoming product launches and strategic investments in laboratory technology.
🚩 Red Flags
- Forward-looking statements highlight risks regarding the ability to operate on a profitable basis.
- Risks noted regarding potential inability to secure additional financing if needed.
- Potential risks related to reimbursement levels from insurers for existing and new tests.
📋 Key Facts
- Reported earnings results for the quarter ending December 31, 2023.
- Management is focusing on 'Labs of the Future' strategy and EMR integrations.
- Planned introduction of several new products in H2 2024 or early 2025: Foresight Universal Plus, FirstGene, Precise Tumor (relaunch), Precise Liquid, and Precise MRD for research use.
Myriad Genetics, Inc. provided an investor presentation at the J.P. Morgan Healthcare Conference, reaffirming its fiscal year 2023 guidance and providing preliminary fourth quarter results.
🚩 Red Flags
- Preliminary financial data is unaudited and subject to change during year-end closing.
- Forward-looking statements include risks regarding reimbursement levels, competition, and potential financing needs.
📋 Key Facts
- Reaffirmed full-year 2023 revenue and non-GAAP guidance previously issued on Nov 6, 2023.
- Expected Q4 2023 revenue: $196M - $197M.
- Expected Q4 2023 adjusted EPS: $0.02 to $0.03; GAAP EPS: ($0.35) to ($0.36).
- Projected FY 2023 revenue growth of at least 10% year-over-year.
- Company expects to achieve positive adjusted operating cash flow in Q4 2023.
- Preliminary gross margins (GAAP and adjusted) for Q4 2023 are approximately 70%.
- Prenatal volume growth in Q4 2023 is expected to be at least 10% year-over-year.